What is Eli Lilly and Company's P/E and P/B ratio?

Eli Lilly and Company has a P/E ratio of 43.9 and a P/B ratio of 34.39.

What is Eli Lilly and Company's debt-to-equity ratio?

Eli Lilly and Company has a debt-to-equity ratio of 1.62.

How much does Eli Lilly and Company owe compared with what it owns?

Eli Lilly and Company owes $0.76 for every $1 it owns (balance sheet Jun 2026), which is moderate.

Does Eli Lilly and Company have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

Eli Lilly and Company has no active red flags. It has 1 yellow flag (PosiYellow stress signals, 1/10 points): Pledge-related SEC filings found.

Where can I read the latest news about Eli Lilly and Company?

Recent headlines about Eli Lilly and Company from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Eli Lilly and Company have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Eli Lilly and Company's current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

Eli Lilly and Company

Q: What is Eli Lilly and Company's Positivity rank?

Eli Lilly and Company is ranked #6,212 of 6,774 companies globally and #3,536 of 4,000 in United States on PositoAI, with a Positivity Score of 2,100.

NYSE: LLY · Healthcare

Positivity Index

#6,212 / 6,774

Global

#3,536 / 4,000

United States

Positivity Score

2,100

Rank→

PosiRed: no active red flags · PosiYellow: 1 yellow flag (1/10 points) View flag history →

PosiYellow · yellow flag (stress signal)

Pledge-related SEC filings found

Found 3 SEC Form 4 filing(s) mentioning 'pledged' for this company's insiders. No exact percentage is available from this source (unlike India's BSE disclosures) — this flags that pledge-related activity exists and is worth reviewing directly on SEC EDGAR, not a computed magnitude.

More details →

Eli Lilly and Company — Overview & Financial Snapshot

Eli Lilly and Company (NYSE: LLY) is a Healthcare company, ranked #6,212 of 6,774 companies globally and #3,536 of 4,000 in United States on PositoAI, with a Positivity Score of 2,100. Its market capitalisation is ₹109.99 lakh Cr ($1.17T), P/E ratio is 43.9 and P/B ratio is 34.39. It has no active red flags (PosiRed) and 1 yellow flag (PosiYellow, 1/10 points): Pledge-related SEC filings found.

For financial statements, ratio trends and score history, Go Deep →

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company has a strategic partnership with Metis TechBio Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.